Liver-targeted chemo boost shows promise for tough bile duct cancer
NCT ID NCT07304388
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tested whether adding a liver-directed chemotherapy (HAIC) to a standard drug combination (Gemox, lenvatinib, and toripalimab) could help people with advanced bile duct cancer live longer without the disease getting worse. 96 adults whose cancer could not be removed by surgery took part. The goal was to see if the extra treatment improved 6-month progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.